Roche Holding has reported its quarterly sales, which were impacted by performance of a key eye drug. The company has also made other announcements, including the launch of a new FDA-cleared test and the appointment of a new leader for its North America diagnostics business. Despite some challenges, Roche is maintaining its full-year outlook, with sales rising in the first half of the year.